Biotherapeutics

Biotherapeutics is a critical therapeutic modality to tackle many important disease targets.  Monoclonal antibody represents the single largest class of molecules, and has a proven track record in targeting soluble proteins and cell surface receptors. 

Crown Bioscience has developed state of the art Target-to-Therapeutics capabilities to help accelerate your drug development process and allow you to spend your valuable time focusing on your core competency.  Our proprietary HuPhage^TM antibody phage display system, as well as robust production and protein engineering capability have been deployed to support multiple drug development programs by both large pharmaceutical and small biotech companies.  Combined with our strong biology expertise, we can either engage our partners in a fully integrated drug discovery program (i.e. Crown Bioscience will deliver an IND candidate from target), or provide support for specific portion of your internal programs.